Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, Kiserud CE.

Bone Marrow Transplant. 2019 Nov 19. doi: 10.1038/s41409-019-0745-4. [Epub ahead of print]

PMID:
31745250
2.

Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma.

Bai B, Vodák D, Nakken S, Wise JF, Blaker YN, Lingjærde OC, Brodtkorb M, Hilden V, Trøen G, Lorenz S, Lawrence MS, Myklebost O, Meza-Zepeda L, Beiske K, Hovig E, Smeland EB, Holte H, Myklebust JH.

Blood. 2019 Nov 13;134(Supplement_1):20. doi: 10.1182/blood-2019-128403.

PMID:
31723999
3.

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.

Lagerlöf I, Holte H, Glimelius I, Björkholm M, Enblad G, Erlanson M, Fluge Ø, Fohlin H, Fosså A, Goldkuhl C, Gustavsson A, Johansson AS, Linderoth J, Nome O, Palma M, Åkesson L, Østenstad B, Raud C, Glimelius B, Molin D.

Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16232. [Epub ahead of print]

PMID:
31612478
4.

Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.

Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, Holte H.

Acta Oncol. 2019 Aug 20:1-5. doi: 10.1080/0284186X.2019.1652765. [Epub ahead of print] No abstract available.

PMID:
31429371
5.

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.

Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ.

Blood Adv. 2019 Jul 23;3(14):2230-2236. doi: 10.1182/bloodadvances.2019000151.

6.

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Alkodsi A, Cervera A, Zhang K, Louhimo R, Meriranta L, Pasanen A, Leivonen SK, Holte H, Leppä S, Lehtonen R, Hautaniemi S.

Leukemia. 2019 Nov;33(11):2662-2672. doi: 10.1038/s41375-019-0509-6. Epub 2019 Jun 11.

PMID:
31186494
7.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.

Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.

8.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. No abstract available.

9.

Reply to M. Sorigue et al.

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. No abstract available.

PMID:
30735430
10.

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE.

J Clin Oncol. 2019 Mar 20;37(9):703-713. doi: 10.1200/JCO.18.01652. Epub 2019 Feb 6.

PMID:
30726176
11.

Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE.

Acta Oncol. 2019 May;58(5):690-699. doi: 10.1080/0284186X.2018.1558370. Epub 2019 Jan 30.

PMID:
30696346
12.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

13.

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators.

N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

PMID:
30501490
14.

Very early mobilisation in cases of acute stroke.

Fure B, Holte HH, Hov L, Vist GE, Kateraas LH, Indredavik B.

Tidsskr Nor Laegeforen. 2018 Oct 15;138(17). doi: 10.4045/tidsskr.17.0924. Print 2018 Oct 30. Norwegian.

15.

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. [Epub ahead of print]

PMID:
30285560
16.

Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity.

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE.

Bone Marrow Transplant. 2019 Apr;54(4):607-610. doi: 10.1038/s41409-018-0342-y. Epub 2018 Sep 27. No abstract available.

PMID:
30262906
17.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

18.

Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL.

Da Broi M, Jahr G, Beiske K, Holte H, Meling TR.

Blood Cells Mol Dis. 2018 Nov;73:25-32. doi: 10.1016/j.bcmd.2018.08.005. Epub 2018 Aug 30.

PMID:
30217760
19.

[Does exercise help in severe mental disorders?].

Underland V, Holte HH, Vist GE.

Tidsskr Nor Laegeforen. 2018 Aug 21;138(12). doi: 10.4045/tidsskr.18.0521. Print 2018 Aug 21. Norwegian. No abstract available.

20.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

PMID:
30095158
21.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

22.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B; Aristotle Consortium.

Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.

PMID:
30078408
23.

Effect of requiring a general practitioner at scenes of serious injury: A systematic review.

Straumann GSH, Austvoll-Dahlgren A, Holte HH, Wisborg T.

Acta Anaesthesiol Scand. 2018 Oct;62(9):1194-1199. doi: 10.1111/aas.13174. Epub 2018 Jun 22.

PMID:
29932207
24.

Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?

Meling TR, Latysheva A, Da Broi M, Jahr G, Holte H Jr, Beiske K, Emblem KE.

Neuroradiology. 2018 Jul;60(7):703-713. doi: 10.1007/s00234-018-2038-9. Epub 2018 May 27.

PMID:
29804159
25.

Sample-Index Misassignment Impacts Tumour Exome Sequencing.

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E.

Sci Rep. 2018 Mar 28;8(1):5307. doi: 10.1038/s41598-018-23563-4.

26.

Effect of General Practitioner’s Presence at Accident Site: A Systematic Review [Internet].

Straumann GH, Austvoll‐Dahlgren A, Holte HH, Wisborg T.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Jun 13.

27.

Co-organization of General Practitioners with Other Primary Health Care Services: A Systematic Review [Internet].

Forsetlund L, Holte HH, Ding Y, Lidal IB.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Nov 10.

28.

Psychosocial Treatment with or without Antipsychotics for Patients with Active Psychosis: A Systematic Review [Internet].

Holte HH, Austvoll-Dahlgren A, Straumann GH.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 29.

29.

Effect of Physical Activity without Use of Antipsychotics Compared to Physical Activity and Antipsychotics for Patients with Active Psychosis: A Systematic Review [Internet].

Dahm KT, Holte HH, Dalsbø TK, Straumann GH, Reinar LM.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 29.

30.

Stretching After Treatment with Botulinum Toxin for Adult Patients with Spasticity: A Systematic Mapping Review [Internet].

Underland V, Holte HH, Straumann GH, Hov L, Vist GE.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Dec 22.

31.

Systematic Reviews on Preventing Catheter-Associated Urinary Tract Infection [Internet].

Holte HH, Underland V, Hafstad E.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Dec 16.

32.

Systematic Reviews on Preventing Pressure Ulcers: A Systematic Review [Internet].

Holte HH, Underland V, Hafstad E.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Dec 15.

33.
34.

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22.

35.

The role of surgery in intracranial PCNSL.

Jahr G, Da Broi M, Holte H Jr, Beiske K, Meling TR.

Neurosurg Rev. 2018 Oct;41(4):1037-1044. doi: 10.1007/s10143-018-0946-0. Epub 2018 Jan 27.

PMID:
29383600
36.

The Effect of Rehabilitation on Social and Community Participation [Internet].

Holte HH, Ranheim T, Flottorp S.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2009 Nov.

37.

Supplemented Primary Care Units Compared to Hospitalisation [Internet].

Forsetlund L, Holte HH, Straumann GH.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2014 Dec.

38.

Triagesystems for Emergency Medical Services – Pre-Hospital and at Hospital Admission [Internet].

Lidal IB, Holte HH, Gundersen MW.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Dec.

39.

Organization of Physical Medicine and Rehabilitation in Hospitals [Internet].

Gjerberg E, Flottorp S, Holte HH.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Sep.

40.

Effect of Single Room vs. Contact Isolation Containment Rooms [Internet].

Holte HH, Vist GE, Straumann GH.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2013 Dec.

41.

Task Sharing for Selected Health Services in Hospitals [Internet].

Forsetlund L, Vist GE, Dalsbø TK, Straumann GH, Underland V, Norderhaug IN, Holte HH.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2013 Sep.

42.

Effect of Patient Hotels for Hospitals and Patient [Internet].

Holte HH, Harboe I, Vist GE.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 May.

43.

Discharging Patients with Chronic Disease: Effect of Various Forms of Cooperation Between Hospital and the Community Health Service [Internet].

Holte HH, Lidal IB, Gundersen MW.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2013 Jun.

44.

Intermediate Care Units and Hospital at Home for Acute Exacerbations of COPD [Internet].

Jeppesen E, Gundro Brurberg K, Lidal IB, Holte HH, Vis GE.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 May.

45.

Skills Laboratories: Virtual Training of Manual and Practical Skills [Internet].

Hviding K, Austvoll-Dahlgren A, Holte HH, Flottorp S.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2009 Mar.

46.

Mercury Exposure in Dental Personnel [Internet].

Holte HH, Dalsbø TK, Vist GE, Steiro A, Lidal IB, Gundersen M, Merete Reinar L, Jamtvedt G.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Jan.

47.

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Dec 15;7(12):654. doi: 10.1038/s41408-017-0033-8.

48.

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB.

Acta Oncol. 2018 Jun;57(6):773-781. doi: 10.1080/0284186X.2017.1406137. Epub 2017 Nov 24.

PMID:
29171324
49.

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C.

J Nucl Med. 2018 Apr;59(4):704-710. doi: 10.2967/jnumed.117.195347. Epub 2017 Aug 28.

50.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Aug 25;7(8):e596. doi: 10.1038/bcj.2017.71.

Supplemental Content

Support Center